{
    "xml": "<topic id=\"PHP34531\" outputclass=\"drugClass\" rev=\"1.31\" type=\"drugClass\" namespace=\"/drug-classes/angiotensin-ii-receptor-antagonists\" basename=\"angiotensin-ii-receptor-antagonists\" title=\"ANGIOTENSIN-II RECEPTOR ANTAGONISTS\">\n<title>ANGIOTENSIN-II RECEPTOR ANTAGONISTS</title>\n<topic id=\"PHP39650\" outputclass=\"contraindications\" rev=\"1.18\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">The combination of an angiotensin-II receptor antagonist with aliskiren is contra-indicated in patients with an eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>\n</ph>; <ph outputclass=\"contraindication\">the combination of an angiotensin-II receptor antagonist with aliskiren is contra-indictated in patients with diabetes mellitus</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39658\" outputclass=\"cautions\" rev=\"1.23\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Afro-Caribbean patients&#8212;particularly those with left ventricular hypertrophy (may not benefit from an angiotensin-II receptor antagonist)</ph>; <ph outputclass=\"caution\">aortic or mitral valve stenosis</ph>; <ph outputclass=\"caution\">elderly (lower initial doses may be appropriate)</ph>; <ph outputclass=\"caution\">hypertrophic cardiomyopathy</ph>; <ph outputclass=\"caution\">patients with a history of angioedema</ph>; <ph outputclass=\"caution\">patients with primary aldosteronism (may not benefit from an angiotensin-II receptor antagonist)</ph>; <ph outputclass=\"caution\">renal artery stenosis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39607\" outputclass=\"interactions\" rev=\"1.15\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (angiotensin-II receptor antagonists).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39566\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hyperkalaemia</ph>; <ph outputclass=\"sideEffect\">angioedema (may be delayed onset)</ph>; <ph outputclass=\"sideEffect\">symptomatic hypotension including dizziness (particularly in patients with intravascular volume depletion, e.g. those taking high-dose diuretics)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39598\" outputclass=\"pregnancy\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; neonatal skull defects and oligohydramnios have also been reported.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39664\" outputclass=\"breastFeeding\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39583\" outputclass=\"renalImpairment\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Use with caution, starting with low dose, and adjust according to response.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39536\" outputclass=\"monitoringRequirements\" parent=\"/drug-classes/angiotensin-ii-receptor-antagonists\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor plasma-potassium concentration, particularly in the elderly and in patients with renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugClasses\" href=\"#drugClasses\" title=\"Drug classes\" namespace=\"/drug-classes\">Drug classes</xref>\n</parents>\n<drugs>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1209\" title=\"CANDESARTAN CILEXETIL\" namespace=\"/drugs/candesartan-cilexetil\">CANDESARTAN CILEXETIL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1211\" title=\"EPROSARTAN\" namespace=\"/drugs/eprosartan\">EPROSARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1213\" title=\"IRBESARTAN\" namespace=\"/drugs/irbesartan\">IRBESARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1219\" title=\"LOSARTAN POTASSIUM\" namespace=\"/drugs/losartan-potassium\">LOSARTAN POTASSIUM</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1227\" title=\"OLMESARTAN MEDOXOMIL\" namespace=\"/drugs/olmesartan-medoxomil\">OLMESARTAN MEDOXOMIL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1239\" title=\"TELMISARTAN\" namespace=\"/drugs/telmisartan\">TELMISARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1245\" title=\"VALSARTAN\" namespace=\"/drugs/valsartan\">VALSARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP18478\" title=\"AZILSARTAN MEDOXOMIL\" namespace=\"/drugs/azilsartan-medoxomil\">AZILSARTAN MEDOXOMIL</xref>\n</drugs>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugClasses\" href=\"#drugClasses\" namespace=\"/drug-classes\" title=\"Drug classes\" count=\"1\" rel=\"link\">Drug classes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1209\" namespace=\"/drugs/candesartan-cilexetil\" title=\"CANDESARTAN CILEXETIL\" count=\"1\" rel=\"link\">CANDESARTAN CILEXETIL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1211\" namespace=\"/drugs/eprosartan\" title=\"EPROSARTAN\" count=\"1\" rel=\"link\">EPROSARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1213\" namespace=\"/drugs/irbesartan\" title=\"IRBESARTAN\" count=\"1\" rel=\"link\">IRBESARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1219\" namespace=\"/drugs/losartan-potassium\" title=\"LOSARTAN POTASSIUM\" count=\"1\" rel=\"link\">LOSARTAN POTASSIUM</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1227\" namespace=\"/drugs/olmesartan-medoxomil\" title=\"OLMESARTAN MEDOXOMIL\" count=\"1\" rel=\"link\">OLMESARTAN MEDOXOMIL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1239\" namespace=\"/drugs/telmisartan\" title=\"TELMISARTAN\" count=\"1\" rel=\"link\">TELMISARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP1245\" namespace=\"/drugs/valsartan\" title=\"VALSARTAN\" count=\"1\" rel=\"link\">VALSARTAN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP18478\" namespace=\"/drugs/azilsartan-medoxomil\" title=\"AZILSARTAN MEDOXOMIL\" count=\"1\" rel=\"link\">AZILSARTAN MEDOXOMIL</xref>\n</links>\n</topic>",
    "id": "PHP34531",
    "outputclass": "drugClass",
    "rev": "1.31",
    "type": "drugClass",
    "namespace": "/drug-classes/angiotensin-ii-receptor-antagonists",
    "basename": "angiotensin-ii-receptor-antagonists",
    "title": "ANGIOTENSIN-II RECEPTOR ANTAGONISTS",
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "The combination of an angiotensin-II receptor antagonist with aliskiren is contra-indicated in patients with an eGFR less than 60 mL/minute/1.73 m2",
                "html": "The combination of an angiotensin-II receptor antagonist with aliskiren is contra-indicated in patients with an eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>"
            },
            {
                "type": "contraindications",
                "textContent": "the combination of an angiotensin-II receptor antagonist with aliskiren is contra-indictated in patients with diabetes mellitus",
                "html": "the combination of an angiotensin-II receptor antagonist with aliskiren is contra-indictated in patients with diabetes mellitus"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Afro-Caribbean patients&#8212;particularly those with left ventricular hypertrophy (may not benefit from an angiotensin-II receptor antagonist)",
                "html": "Afro-Caribbean patients&#8212;particularly those with left ventricular hypertrophy (may not benefit from an angiotensin-II receptor antagonist)"
            },
            {
                "type": "cautions",
                "textContent": "aortic or mitral valve stenosis",
                "html": "aortic or mitral valve stenosis"
            },
            {
                "type": "cautions",
                "textContent": "elderly (lower initial doses may be appropriate)",
                "html": "elderly (lower initial doses may be appropriate)"
            },
            {
                "type": "cautions",
                "textContent": "hypertrophic cardiomyopathy",
                "html": "hypertrophic cardiomyopathy"
            },
            {
                "type": "cautions",
                "textContent": "patients with a history of angioedema",
                "html": "patients with a history of angioedema"
            },
            {
                "type": "cautions",
                "textContent": "patients with primary aldosteronism (may not benefit from an angiotensin-II receptor antagonist)",
                "html": "patients with primary aldosteronism (may not benefit from an angiotensin-II receptor antagonist)"
            },
            {
                "type": "cautions",
                "textContent": "renal artery stenosis",
                "html": "renal artery stenosis"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (angiotensin-II receptor antagonists).",
                "html": "<p>Appendix 1 (angiotensin-II receptor antagonists).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hyperkalaemia",
                        "html": "Hyperkalaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "angioedema (may be delayed onset)",
                        "html": "angioedema (may be delayed onset)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "symptomatic hypotension including dizziness (particularly in patients with intravascular volume depletion, e.g. those taking high-dose diuretics)",
                        "html": "symptomatic hypotension including dizziness (particularly in patients with intravascular volume depletion, e.g. those taking high-dose diuretics)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; neonatal skull defects and oligohydramnios have also been reported.",
                "html": "<p>Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; neonatal skull defects and oligohydramnios have also been reported.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.",
                "html": "<p>Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Use with caution, starting with low dose, and adjust according to response.",
                "html": "<p>Use with caution, starting with low dose, and adjust according to response.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor plasma-potassium concentration, particularly in the elderly and in patients with renal impairment.",
                "html": "<p>Monitor plasma-potassium concentration, particularly in the elderly and in patients with renal impairment.</p>"
            }
        ]
    },
    "drugsInClass": [
        {
            "id": "PHP1209",
            "label": "CANDESARTAN CILEXETIL",
            "type": "drug"
        },
        {
            "id": "PHP1211",
            "label": "EPROSARTAN",
            "type": "drug"
        },
        {
            "id": "PHP1213",
            "label": "IRBESARTAN",
            "type": "drug"
        },
        {
            "id": "PHP1219",
            "label": "LOSARTAN POTASSIUM",
            "type": "drug"
        },
        {
            "id": "PHP1227",
            "label": "OLMESARTAN MEDOXOMIL",
            "type": "drug"
        },
        {
            "id": "PHP1239",
            "label": "TELMISARTAN",
            "type": "drug"
        },
        {
            "id": "PHP1245",
            "label": "VALSARTAN",
            "type": "drug"
        },
        {
            "id": "PHP18478",
            "label": "AZILSARTAN MEDOXOMIL",
            "type": "drug"
        }
    ],
    "backlinks": {},
    "links": {
        "#drugClasses": [
            {
                "id": "drugClasses",
                "label": "Drug classes",
                "type": "#drugClasses"
            }
        ],
        "drug": [
            {
                "id": "PHP1209",
                "label": "CANDESARTAN CILEXETIL",
                "type": "drug"
            },
            {
                "id": "PHP1211",
                "label": "EPROSARTAN",
                "type": "drug"
            },
            {
                "id": "PHP1213",
                "label": "IRBESARTAN",
                "type": "drug"
            },
            {
                "id": "PHP1219",
                "label": "LOSARTAN POTASSIUM",
                "type": "drug"
            },
            {
                "id": "PHP1227",
                "label": "OLMESARTAN MEDOXOMIL",
                "type": "drug"
            },
            {
                "id": "PHP1239",
                "label": "TELMISARTAN",
                "type": "drug"
            },
            {
                "id": "PHP1245",
                "label": "VALSARTAN",
                "type": "drug"
            },
            {
                "id": "PHP18478",
                "label": "AZILSARTAN MEDOXOMIL",
                "type": "drug"
            }
        ]
    }
}